SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RT who wrote (21272)4/23/1999 5:46:00 PM
From: DaiS  Read Replies (2) of 23519
 
RT,

We know from the studies available that some men failing muse responded to alibra, but it is not clear how many men succeed on muse but not on alibra.

It puzzles me the small amount of alprostadil in alibra.....I thought that Vivus might be sacrifing some efficacy to lower price and wider target population. But then I thought that this target population might overlap more with viagra target population than does muse?

I take the point that a small market for muse might not make it commercially viable. I am confident that Vivus have got this one worked out - no I mean it.

DaiS
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News